Evidence map›Paper›PMID 31839880›Full record

ArticleOncotarget2019

M Herman Chui, Susanne K Kjaer, Kirsten Frederiksen, Charlotte G Hannibal, Tian-Li Wang, Russell Vang, Ie-Ming Shih

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Eosinophilic Cells as a Distinct Morphological Feature inDiagnostics (Basel, Switzerland) · 2025
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.Virchows Archiv : an international journal of pathology · 2023
    Article
  10. Review
  11. Review
  12. Pathologic Classification of Ovarian Cancer.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  13. Spectrum ofJCO precision oncology · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

M Herman ChuiDepartment of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Susanne K KjaerUnit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Kirsten FrederiksenUnit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Charlotte G HannibalUnit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Tian-Li WangDepartment of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Russell Vang *Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ie-Ming Shih *Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Danish Cancer Society · DKJohns Hopkins University · USJohns Hopkins Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian serous borderline tumor (SBT) is a known precursor of low-grade serous carcinoma. While most SBTs are cured surgically, some progress to carcinoma and a risk predictor for malignant relapse is needed to ensure vigilant follow-up and additional treatment. Activating mutations in

Indexed as

genotypingmutationovarian serous borderline tumorrisk predictionserous carcinoma

Identifiers

PMID31839880
PMCPMC6901340
OpenAlexW2995145835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.